JAGAN JAKKULA: Open Payments
NPI 1891924957 · REDLANDS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$420 in 16 payments from 6 companies in 2025. Trend: 2023 $21 · 2024 $71 · 2025 $420
Food & beverage: $420
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $193 |
| Supernus Pharmaceuticals, Inc. | 2 | $85 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Neurocrine BioSciences, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
Products named: REXULTI, Qelbree, CAPLYTA, AUSTEDO XR, INGREZZA, TRINTELLIX, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
